Neutrophil to lymphocyte ratio (NLR) may predict survival and efficacy of eribulin in advanced breast cancer patients

Autor:	K. Teraoka, Y. Koshida, M. Nakagawa, N. Sakamoto, Y. Haruyama, M. Nashimoto, R. Nakagawa, E. Fukuma, O. Yu, M. Sakamoto, A. Gen
Rok vydání:	2020
Předmět:	Oncology Cancer Research medicine.medical_specialty business.industry Advanced breast Cancer medicine.disease chemistry.chemical_compound chemistry Internal medicine medicine Neutrophil to lymphocyte ratio business Eribulin
Zdroj:	European Journal of Cancer. 138:S64-S65
ISSN:	0959-8049
DOI:	10.1016/s0959-8049(20)30699-7
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::edd69cdf7f193cb0ac7a0d46980c2eef https://doi.org/10.1016/s0959-8049(20)30699-7 Zobrazit plný text záznamu Full Text from ScienceDirect